Fiche centre
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan — Italy
Essais liés21clinical trials
VilleMilanlocalisation
PaysItalylocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03832998
Essais cliniques associés
21| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Telerehabilitation | SEP | Non applicable | NCT06699095 | HoReConCareMS — Home Rehabilitation as Continuity of Care in MS | ACTIVE_NOT_RECRUITING |
| SPECTRALS — Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches | Sclérose latérale amyotrophique | À vérifier | NCT06856850 | SPECTRALS — Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches | ACTIVE_NOT_RECRUITING |
| EXTRAORDINARY — Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorde | Parkinson | À vérifier | NCT06846658 | EXTRAORDINARY — Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease | ACTIVE_NOT_RECRUITING |
| PROUD — A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism. | Parkinson | Non applicable | NCT05273957 | PROUD — A Model of Hospital-Territory Management Coordinated by a Case Manager to Improve the Care of Patients With Parkinsonism. | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT05123703 | Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT05066217 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| Efgartigimod IV | Myasthénie | À vérifier | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | RECRUITING |
| Cladribine Low Dose | Myasthénie | Phase 3 | NCT06463587 | Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Eptinezumab | Migraine | Phase 3 | NCT05897320 | PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05164172 | REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT04965675 | PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06719141 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | ACTIVE_NOT_RECRUITING |
| LP352 | Épilepsie | Phase 3 | NCT06908226 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | ENROLLING_BY_INVITATION |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06309966 | RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 2 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Neurosurgical Outcome Network | Épilepsie | À vérifier | NCT06724029 | Neurosurgical Outcome Network | RECRUITING |